36 research outputs found

    Strengthening regulatory science in academia:STARS, an EU initiative to bridge the translational gap

    Get PDF
    Truly disruptive medicine innovation and new treatment paradigms tend to start in non-commercial research institutions. However, the lack of mutual understanding between medicine developers and regulators when it comes to medicine development significantly delays or even prevents the access of patients to these innovations. Here, we outline what regulatory-related barriers hamper the translational development of novel products or new treatment paradigms initiated in academia, and propose key steps towards improved regulatory dialogue among academia, funding bodies and regulatory authorities. Moreover, we briefly describe how the STARS (Strengthening Training of Academia in Regulatory Science) project aims to reach out to medicine innovators in academia to bridge the regulatory knowledge gap and enhance this dialogue to facilitate the implementation of academic research findings in clinical practice

    Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making

    Get PDF
    Analyses of healthcare databases (claims, electronic health records [EHRs]) are useful supplements to clinical trials for generating evidence on the effectiveness, harm, use, and value of medical products in routine care. A constant stream of data from the routine operation of modern healthcare systems, which can be analyzed in rapid cycles, enables incremental evidence development to support accelerated and appropriate access to innovative medicines. Evidentiary needs by regulators, Health Technology Assessment, payers, clinicians, and patients after marketing authorization comprise (1) monitoring of medication performance in routine care, including the materialized effectiveness, harm, and value; (2) identifying new patient strata with added value or unacceptable harms; and (3) monitoring targeted utilization. Adaptive biomedical innovation (ABI) with rapid cycle database analytics is successfully enabled if evidence is meaningful, valid, expedited, and transparent. These principles will bring rigor and credibility to current efforts to increase research efficiency while upholding evidentiary standards required for effective decision-making in healthcare

    Nemathelminthen (Rundwürmer)

    No full text

    Wanderungen durch Westfalen

    No full text
    von Gerhard LöbkerIn FrakturErschienen: Bd. 1 -

    Die antiseptische Nachbehandlung der Urethrotomia externa

    No full text

    Treibhauspflanzen

    No full text

    Wurmkrankheit

    No full text

    Wanderungen durch das Weserthal

    No full text
    von Gerhard LöbkerIn Fraktu
    corecore